RESEARCH TRIANGLE PARK, N.C., May 4 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch has been appointed President and Chief Executive Officer. Mr. Moch joined Chimerix as Chief Operating Officer in July 2009, bringing more than 25 years of experience in creating, managing and financing biomedical companies. Mr. Moch will also join the company's Board, for a total of six directors.
George Painter, Ph.D., Chimerix's former President and Chief Executive Officer, has been named Chief Scientific Officer and Chairman of the company's Board. In his new role, Dr. Painter will oversee Chimerix's drug discovery and development efforts and seek opportunities to leverage the company's proprietary platform capabilities and antiviral expertise in the advancement of important new medicines that address global health needs. Seth Rudnick, M.D., General Partner, Canaan Partners and Tim Wollaeger, Managing Director, Sanderling Ventures, formerly Co-Chairmen of the Chimerix Board, remain Directors of the company.
"Ken Moch and George Painter make an outstanding and highly complementary leadership team. Ken and George will each play to their strengths in pursuing the same goal: advancing important antiviral medicines that can save lives," said Mr. Wollaeger on behalf of the Chimerix Board. "Dr. Painter is a world-class innovator and drug developer and his vision has resulted in the discovery and early evaluation of Chimerix's pipeline of powerful antivirals to address such serious viruses as cytomegaloviru
|SOURCE Chimerix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved